抗生素停用策略对重症脓毒症患者死亡率和感染并发症的影响:一项Meta分析与试验序贯分析
该Meta分析与试验序贯分析纳入22项随机临床试验共6046例重症感染或脓毒症患者,评估缩短抗生素疗程的策略(降钙素原指导14项、临床算法2项、固定疗程6项)对死亡率和感染并发症的影响。降钙素原指导使抗生素疗程平均缩短1.23天(95%CI -1.61至-0.85,p<0.001),临床算法指导未显著缩短(-7.41,95%CI -18.18至3.37,p=0.18),固定疗程试验的预期缩短为3至7天。降钙素原指导、临床算法指导及固定疗程均未显著降低死亡率。降钙素原指导的死亡率试验序贯分析未达到获益、 harm或无效的监测边界,临床算法和固定疗程的试验序贯分析累积信息量不足5%。尽管疗程缩短,降钙素原指导(RR 0.93,95%CI 0.84-1.03,p=0.15)和固定疗程(RR 1.06,95%CI 0.74-1.53,p=0.75)均未显著增加治疗失败。
要点
- 降钙素原指导使抗生素疗程平均缩短1.23天(95%CI -1.61至-0.85,p<0.001),但死亡率无显著降低(RR 0.91,95%CI 0.82-1.01,p=0.09)。
- 固定疗程抗生素(预期缩短3至7天)死亡率无显著降低(RR 1.21,95%CI 0.90-1.63,p=0.20),治疗失败无显著增加(RR 1.06,95%CI 0.74-1.53,p=0.75)。
- 临床算法指导抗生素停用未显著缩短疗程(-7.41天,95%CI -18.18至3.37,p=0.18),死亡率无显著降低(RR 0.67,95%CI 0.30-1.54,p=0.35)。
- 降钙素原指导的死亡率试验序贯分析未达到获益、 harm或无效的监测边界(调整CI 0.72-1.10),临床算法和固定疗程的试验序贯分析累积信息量不足5%。
- 降钙素原指导未显著增加治疗失败(RR 0.93,95%CI 0.84-1.03,p=0.15)。
适用人群与场景
- 重症监护病房中患有感染或脓毒症的患者(纳入随机临床试验的人群)。
处置流程与药物剂量
- 降钙素原指导抗生素治疗:14项随机临床试验,与抗生素疗程缩短1.23天相关(95%CI -1.61至-0.85,p<0.001)。
- 临床算法指导抗生素治疗:2项随机临床试验,抗生素疗程变化-7.41天(95%CI -18.18至3.37,p=0.18)。
- 固定疗程抗生素治疗:6项随机临床试验,预期缩短3至7天。
研究设计与关键结果
- 研究类型:系统评价与Meta分析及试验序贯分析,纳入22项随机临床试验,共6046例重症感染或脓毒症患者。
- 降钙素原指导 vs 对照:抗生素疗程平均差-1.23天(95%CI -1.61至-0.85,p<0.001);死亡率RR 0.91(95%CI 0.82-1.01,p=0.09);治疗失败RR 0.93(95%CI 0.84-1.03,p=0.15)。
- 临床算法指导 vs 对照:抗生素疗程平均差-7.41天(95%CI -18.18至3.37,p=0.18);死亡率RR 0.67(95%CI 0.30-1.54,p=0.35)。
- 固定疗程 vs 对照:死亡率RR 1.21(95%CI 0.90-1.63,p=0.20);治疗失败RR 1.06(95%CI 0.74-1.53,p=0.75)。
- 试验序贯分析:降钙素原指导的死亡率Z曲线未达到获益、 harm或无效的监测边界(调整CI 0.72-1.10);临床算法和固定疗程的试验序贯分析累积信息量小于所需信息量的5%。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析及试验序贯分析,纳入22项随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,降钙素原指导或预设有限疗程可缩短抗生素疗程,但Meta分析与试验序贯分析对死亡率获益尚无定论。
- 作者认为,临床算法指导抗生素停用的数据有限。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate methods of antibiotic duration minimization and their effect on mortality and infectious complications in critically ill patients.
DATA SOURCES: A systematic search of PubMed, Embase (via Ovid), clinicaltrials.gov, and the Cochrane Central Register of Controlled Trials (via Wiley) (CENTRAL, Issue 2, 2015).
STUDY SELECTION: Randomized clinical trials comparing strategies to minimize antibiotic duration (days) for patients with infections or sepsis in intensive care.
DATA EXTRACTION: A systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Dichotomous data are presented as relative risk (95% CIs) and p value, and continuous data are presented as mean difference (CI) and p value.
DATA SYNTHESIS: We included 22 randomized clinical trials (6,046 patients). Strategies to minimize antibiotic use included procalcitonin (14 randomized clinical trials), clinical algorithms (two randomized clinical trials), and fixed-antibiotic duration (six randomized clinical trials). Procalcitonin (-1.23 [-1.61 to -0.85]; p < 0.001), but not clinical algorithm-guided antibiotic therapy (-7.41 [-18.18 to 3.37]; p = 0.18), was associated with shorter duration of antibiotic therapy. The intended reduction in antibiotic duration ranged from 3 to 7 days in fixed-duration antibiotic therapy randomized clinical trials. Neither procalcitonin-guided antibiotic treatment (0.91 [0.82-1.01]; p = 0.09), clinical algorithm-guided antibiotic treatment (0.67 [0.30-1.54]; p = 0.35), nor fixed-duration antibiotics (1.21 [0.90-1.63]; p = 0.20) were associated with reduction in mortality. Z-curve for trial sequential analyses of mortality associated with procalcitonin-guided therapy did not reach the trial sequential monitoring boundaries for benefit, harm, or futility (adjusted CI, 0.72-1.10). Trial sequential analyses for mortality associated with clinical algorithm and fixed-duration treatment accumulated less than 5% of the required information size. Despite shorter antibiotic duration, neither procalcitonin-guided therapy (0.93 [0.84-1.03]; p = 0.15) nor fixed-duration antibiotic therapy (1.06 [0.74-1.53]; p = 0.75) was associated with treatment failure.
CONCLUSIONS: Although the duration of antibiotic therapy is reduced with procalcitonin-guided therapy or prespecified limited duration, meta-analysis and trial sequential analyses are inconclusive for mortality benefit. Data on clinical algorithms to guide antibiotic cessation are limited.
参考来源
- Arulkumaran N, Khpal M, Tam K, et al. Effect of Antibiotic Discontinuation Strategies on Mortality and Infectious Complications in Critically Ill Septic Patients: A Meta-Analysis and Trial Sequential Analysis. Crit Care Med. 2020. PMID: 32191414. doi:10.1097/CCM.0000000000004267
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。